

Index

- abreaction 153
 acetazolamide 77
 acupuncture 18, 115, 138
 addiction 63
 confirmed or suspected,
 management of 70
 defined 63
 pseudoaddiction 64
 addiction-related problems, chronic
 noncancer pain (CNCP) 64
 adrenocorticotrophic hormone
 (ACTH) 54
 stress, beta-endorphin ACTH 54
 aerobic exercise 102, 135–136
 affective/anxiety disorders 4
 alexithymia 121, 136, 150
 allodynia, cutaneous allodynia (CA)
 5, 100
 Allodynia Symptom Checklist
 (ASC-12) 5
 alpha-lipoic acid 135
 alternative medical systems 137–141
 amitriptyline 16, 17, 26
 AMPA antibodies 81
 analgesics, over-the-counter 100
 anticonvulsants 26, 58, 155
 antidepressants 26, 58
 dose range 33
 insufficient response 35
 pain disorder 154
 side effects 34
 switch into mania 37
 and testosterone 36
 see also tricyclic antidepressants
 antiepileptics 122
 antiepileptics (AEDs) 17
 suicide risk 39
 antipsychotics 35
 anxiety and chronic headache 45
 connections between 46
 interconnectedness 45–47
 MOH 47
 neurobiological connections 46
 psychological connections 46
 anxiety disorders, defined 42
 anxiety and (primary) headache 2, 4,
 42–51
 biofeedback training 49
 cognitive-behavioral therapy (CBT)
 14, 36, 48–51, 112–114
 defined 42
 generalized anxiety disorder (GAD) 43
 relaxation training 48, 49
 screening and assessment 47–48
 triggers 50
 types 42
 appraisal 106
 concept 55
 argininosuccinate synthetase and
 argininosuccinate lyase 88
 Argyll Robertson pupils 87
 Ask–tell–ask question sequence 126
 aspartame 14
 aspirin 25, 38
 astrocytes 13
 ATP7B gene 83
 attachment style 123
 dismissive attachment style 124
 fearful attachment 124
 preoccupied attachment 124
 attachment system 123–124
 auras 10, 12, 31
 sensory 10
 autogenic training (AT) 108
 autoimmune disease, limbic
 encephalitis (LE) 81
 avoidance (feared stimuli) 42

 barbiturates
 dependence 68
 see also butalbital
 basilar migraine 13
 Beck Depression Inventory (BDI)-II
 32, 35
 behavior, nonverbal 125
 behavior therapy (BT) 36
 behavioral headache management 47–51
 Behçet's disease 79
 intracranial hypertension 79
 benzodiazepines, dependence 68
 beta-blockers 16, 35
 biofeedback 110–112
 blood-volume–pulse feedback BP
 (BVP-FB) 60
 electromyographic (EMG)
 biofeedback 49, 109, 111
 meta-analysis 60
 stress management 60, 110–112
 thermal biofeedback 49
 training 49
 biofeedback-assisted autogenic training
 (AT) 109
 bipolar affective disorders 30–39
 associated with migraine 31–32
 prevalence 33
 suicide attempts 32
 with/without aura 31
 classification 30
 hypomania episodes 30
 I and II 30
 switching phenomenon 37
 treatment 37
 see also depression
 bipolar spectrum disorders 3
 blood flow, brain changes 13
 borderline personality disorder 122
 botulinum toxins 5, 18, 26, 98, 101
 A 18
 medication overuse headache
 (MOH) 98, 101
 onabotulinum, side effects 18
 bradykinin 12
 brain
 deep brain stimulation (DBS) 141
 hyperexcitable cortex 12
 systemic disease involving brain 78
 brain injury (TBI) 86
 brain tumors 78
 intracranial hypertension 78
 butalbital 16, 26, 68
 dependence 68
 butalbital-containing compounds 26
 butorphanol, dependence 67–68
 butterbur (*Petasites*) 18, 134

 CACNL1A4 gene 77
 caffeine 14, 26, 99, 100
 MOH 69
 calcitonin gene-related peptide (CGRP)
 12, 14
 calcium channel blockers 16
 CANA1A gene 14
 candesartan 17
 cannabis 68

- carbamazepine 17, 38, 122
 carbamyl phosphatase synthetase 88
 CASPR2 autoantibodies 81
 catechol-O-methyl transferase (COMT) 122
 cerebrovascular disease 78
 post-partum 78
 Charles Bonnet syndrome 79
 Chinese medicine 137
 chiropractic 140
 chocolate 14
 cholecalciferol (vitamin D3) replenishment 133
 chronic cluster 97
 chronic daily headache (CDH) 95–103
 classification and diagnosis 96–98
 clinical presentation 99–100
 default diagnosis 103
 defined 95
 diagnostic pearls 97
 epidemiology 98
 new daily persistent headache 97
 opioids 64
 pathophysiology 98–99
 primary vs. secondary headache 95
 risk factors 96
 secondary headaches mimicking primary CDH 96
 short-duration vs. long-duration 97
 tension-type headache 97, 98
 transformed migraine 97, 98
 chronic migraine (CM) 1
 defined 6
 chronic noncancer pain (CNCP) 64
 addiction-related problems 64
 chronic tension-type headache (CTTH) 21
 coenzyme Q10 18, 134
 cognitive therapy (CT) 36
 cognitive-behavioral therapy (CBT) 14, 36, 48–51, 58–60, 112–114, 160–161
 clinician–patient relationship 112
 coping skills 114
 motivation for change 112
 psycho education 112
 requiring trained personnel 59
 self-efficacy 113
 stress management 49, 112–114
 communication strategy 126
 co-morbidity
 bidirectional causal model 3
 case controlled studies 2
 clinical importance of 5–6
 cross-sectional studies 2
 defined 1
 depressive and anxiety disorders 2
 epidemiology 1–6
 mechanisms 3–5
 prospective or cohort studies, defined 2
 psychiatric comorbidities 2–3
 complementary/alternative medicine (CAM) 115, 131–141, 155
 acupuncture 115
 approaches to headache 131–141
 hypnosis and imagery 109
 meditation 109
 scope 132–133
 yoga 114
 compliance-enhancing strategies 113
 conversion disorder 151–153
 abreaction 153
 clinical features of headache 152
 course 152
 definition and clinical features 151
 epidemiology 152
 treatment 152–153
 cortex, hyperexcitable 12
 cortical spreading depression (CSD) 11–13
 corticosteroid binding globulin (CBG) 55
 corticotropin releasing hormone (CRH) 54
 cortisol 54
 production 85
 countertransference reactions 125
 cranial electrotherapy stimulation (CES) 141
 craniosacral manipulation 140
 curcumin 133
 Cushing's syndrome 85
 cutaneous allodynia (CA) 5
 cyclothymic disorder 31
 cytokines 14
 deception syndromes 157–159
 deep brain stimulation (DBS) 141
 delusional disorder 75, 76
 of guilt 30
 depression
 and/or panic attacks/anxiety/stress 56
 bipolar, evidence-based treatments 37
 episode 30
 major depressive disorder with migraine 31
 psychotherapy benefits 36
 screening tools 32
 see also bipolar affective disorders
 depressive and anxiety disorders 2
 dextromethorphan 17
 diffuse axonal injury 86
 diffusion tensor imaging (DTI) 86
 diffusion tensor tractography 86
 dihydroergotamine (DHE) 15
 divalproex 16, 122
 dopamine antagonists 77
 dopamine deficiency, link with depression 5
 drug dependence 63–71
 defined 63
 management of 70
 see also medication overuse headache (MOH)
 drug-induced psychosis and headache 83
 DSM-IV, somatization disorders 151
 DSM-IV organization 119
 DSM-IV trait domains 120
 DSM-V, revision 119
 eating behaviors 102
 electrical stimulation of the brain (ESB) 141
 electroencephalogram feedback (EEG-FB) 60
 electroencephalography (EEG) 90
 electromagnetic stimulation 141
 electromyographic biofeedback (EMG-FB) 49, 60, 109, 111
 emotion 150
 emotional freedom technique (EFT) 137
 endocrine disorders, thyroid disease 80
 epidemiology
 Berkson bias 1
 chronic daily headache (CDH) 98
 comorbidities of headache 1–6
 defined 1
 mood disorders 31–32
 tension-type headache (TTH) 23–24
 epilepsy 77
 post-ictal psychosis 77
 episodic headaches, chronification 98, 106
 episodic migraine (EM) 1, 23, 57
 chronic daily headache and PTSD 57
 defined 6
 episodic tension-type headache (ETTH) 21, 23
 pain thresholds 25
 prevalence 23
 vs. migraine headache 23
 ergotamines 12, 15, 38
 exercise 102, 135–136
 exposure 48
 eye movement desensitization and reprocessing (EMDR) 137
 factitious disorder 157–159
 false beliefs, medications 36
 familial hemiplegic migraines (FHM) 77
 fears 122
 annihilation 123
 injury 123

Index

- fears (cont.)
 loss of love and fear of loss of
 control 123
 punishment 123
 strangers 123
 feverfew 18, 133
 foods, common migraine
 triggers 14
 fortification spectra 12
- GABA antibodies 81
 GABA-nergic function 46
 gabapentin 17
 galvanic skin response training
 (GSR-FB) 60
 generalized anxiety disorder (GAD) 43
 CBT 48
 Germany, West Germany Headache
 Center 61
 giant cell arteritis (GCA) 79
Ginkgo biloba extract (GBE) 135
- hallucinations
 Charles Bonnet syndrome 79
 tactile 85
 visual 85
 headache, IHS classification 150
 hemicrania continua 9, 10, 95, 97
 hemiplegic migraine 14, 77
 hepatolenticular degeneration
 83–85
 homeopathy 139–140
 5-HT₁ receptors 15
 5-HT₂ receptors 98
 hydrocephalus 87, 90
 hyperexcitable cortex 12
 hypnosis and imagery 109, 136–137
 hypochondriasis 156–157
 hypothalamic–pituitary–adrenal axis
 (HPA) and cortisol axis 54, 55
- ibuprofen 25, 38
 idiopathic intracranial hypertension
 (IHH) 86
 immunosuppressants 81, 91
 Indian medicine 139
 infectious disease 87
 inflammation 133
 information gathering 126
 internet-based relaxation 110
 interpersonal psychotherapy theory
 (IPT) 36, 37
 intracranial hypertension 78
 isotretinoin (vitamin A) 86
- Kayser–Fleischer ring 83
- lamotrigine 38
 LGI1 antibodies 81
- lifestyle, exercise and dietary
 considerations 133
 limbic encephalitis (LE) 81, 91
 lisinopril 17
 lithium 37, 38
- magnesium 18
 deficiency 133
 malingering 69–70
 management 159
 opioids 70
 Personality Assessment Inventory 69
 prevalence 159
 malingering factitious disorder
 157–159
- malpractice complaints 126
 manual therapies 140–141
 medical interactions, psychodynamic
 issues 124–125, 127
 medication overuse headache (MOH)
 47, 63, 64, 95, 98–99
 central sensitization 99
 clinical presentation 99–100
 default diagnosis 103
 defined 64
 differential diagnosis 100
 onabotulinum toxin A 98, 101
 pathophysiology 98–99
 preventives 98
 prognosis 102–103
 rescue medications 98
 serotonergic pathways 98
 treatment 100–102
- medications
 false beliefs 36
 non-adherence 36
 meditation 109
 MELAS 81–83
 memantine 17
 metabolic disorders 88
 metals, toxic exposure to 87
 methysergide 13
 migraine 9–19
 anxiety disorders in 42
 background 9
 diagnosis and clinical features 9
 dysphrenic 77
 pathophysiology 10
 photophobia 9
 precipitating factors 14
 prodromal symptoms 9
 risk for first-onset major
 depression 56
 and stress, risk for first-onset major
 depression 56
 transformed 97, 98
 treatment 14
 acute treatment 14
 non-medication therapies 14
- ona, side effects 18
 preventive treatment 16
 triptans 14, 15
 triggers 14
 types
 basilar 13
 chronic or transformed 97
 episodic vs. chronic 95
 hemiplegic 14, 77
 unusual forms 13
 with/without aura 9, 10, 31
 migraine disability assessment scale
 (MIDAS) 65
 migraine madness 77
 mind/body-centered medicine 135–137
 Minnesota Multiphasic Personality
 Inventory (MMPI) 69
 mirtazapine 26
 mitochondrial disease 81–83
 mitochondrial oxidative metabolism 134
 monoamine oxidase inhibitors 17
 monosodium glutamate 14
 mood disorders 30–39
 classification 30
 effective treatments 37
 epidemiology 31–32
 medications and interactions 38
 patients 39
 screening and diagnosis 32–33
 treatment 33–39
see also specific disorders
 mood stabilizers 37, 77, 90
 doses 37
 MRSI 83
 multiple sclerosis 87
 muscle contraction headache 24, 75
 myofascial activity, tension-type
 headache (TTH) 25
- naloxone, and tramadol dependence 67
 naproxen 25
 narrative knowledge 126
 nausea 15
 neurobiology of personality 121–122
 neuroimaging 90
 neurokinin 12
 neurokinin-1 receptor antagonists 13
 neuroleptics 90
 neurosarcoidosis 79
 neuroticism 121
 schizotypal patients 122
 new daily persistent headache 95, 97
 non-responders 131
 non-steroidal antiinflammatory
 medications 15
 nonverbal behavior 125
 noradrenergic-serotonin reuptake
 inhibitor 26
 NSAIDs 15, 25

- obesity 14
 obsessive-compulsive disorder (OCD) 44, 121
 occipital nerve stimulator 141
 ocular pathology 79
 olanzapine 18, 37
 omega-3 135
 onconeural antibodies 81
 onobotulinum toxin A 5, 18, 98, 101
 side effects 18
 opioids 16, 26, 64, 154
 chronic daily headache (CDH) 64
 chronic non-cancer pain (CNCP) 64
 Current Opioid Misuse Measure (COMM) 66
 dependence 65–67
 malingering 70
 opiate addiction in pain disorder 154
 Opioid Risk Tool 66
 opiate-induced hyperalgesia (OIH) 65
 Screener and Opioid Assessment for Patients with Pain (SOAPP-R) 66
 oral contraceptives 55
 organophosphate poisoning 87
 ornithine transcarbamylase 88
 osteopathy 140
- pain
 chronic noncancer pain (CNCP) 64
 neurobiological connections 46
 pain disorder 153–155
 antidepressants 154
 definition and clinical features 153
 epidemiology 154
 and headache 154
 opiate addiction 154
 treatment 154–155
 panic disorder 43–44, 48
 paraneoplastic syndrome 81
 parthenolide 133
 patients
 angry patient 126
 clinician – patient relationship 112
 dependent clingers 128
 devaluing patients 127
 entitled demander 129
 help-rejecting complainer 128
 manipulative 128
 motivation for change 112
 narcissistic patient 125
 needy patients 127
 readiness to make change 113
 seductive patients 127
 self-destructive denier 128
 self-efficacy 113
 suspicious patients 127
 withdrawing 127
 see also personality disorders
- Personality Assessment Inventory, malingering 69
 personality disorders 119–129
 10 types 120
 borderline personality disorder 122
 countertransference reactions 125
 defined 119
 diagnosis 119–121
 interpersonal difficulties 122–124
 interpersonal management 125
 management 127–129
 consistency 127
 sympathetic limit setting 127
 treatment contract 127
 medical causes of personality pathology 121
 neurobiology 121–122
 self functioning 121
 trait domains 120
 personality traits and psychiatric disorders, co-morbid conditions in migraine and mediators of stress 55
 pesticides, organophosphate poisoning 87
Petasis hybridus 18, 134
 phenytoin 17
 phobias 44
 phosphenes 12
 PHQ-2 screening 32, 33, 47
 physicians
 emotional attunement 126
 emotional responses to patients 125
 polyunsaturated fatty acids (PUFA) 135
 post-partum cerebrovascular disease 78
 posttraumatic stress disorder (PTSD) 44–45, 56
 diagnosis, precipitating traumatic event 56
 in EM and CDH 57
 pralidoxime 87
 primary vs. secondary headache 95
 progressive muscle relaxation (PMR) 108
 propranolol 16, 38
 prostanoids 12
 psychogenic headaches, first use of term 75
 psychosis and headache
 diagnosis 75
 differential diagnosis 75, 76
 psychotherapeutic approaches 136–137
 psychotherapy, interpersonal psychotherapy theory (IPT) 36, 37
 psychotic disorders 75–91
 brain tumors and 78
 case study 75
 differential diagnosis 75, 76
 laboratory testing 89–90
 new onset psychosis and headache 78–91
 post-ictal 77
 primary neurological with episodes of psychosis and headache 77
 primary psychiatric w. episodes of psychosis and headache 76
 required work-up 88–90
 seizure disorders 77
 treatment considerations 90–91
 work-up for patients with headache and psychosis 88
 psychoticism 121
 public health programs 2
- Qigong 138–139
 quetiapine 18
- radio-iodine imaging, thyroid 90
 rebound headache 101
 regression 124
 reiki 140
 relapse risk factors 101, 102
 relaxation therapy (RT) 108–109
 autogenic training (AT) 108
 hypnosis and imagery 109
 meditation 109
 progressive muscle relaxation (PMR) 108
 relaxation training 48, 49
 riboflavin 18, 134
 role abuse 123
 role bias 123
 role disagreement 123
 role discord 123
- sarcoidosis 79
 SCN1A gene 14
 secondary headaches 21, 95
 mimicking primary CDH 96
 selective norepinephrine reuptake inhibitors (SNRIs) 13, 17, 18, 26, 34, 155
 use with triptans 34
 selective serotonin reuptake inhibitors (SSRIs) 13, 17, 18, 33, 155
 action 33
 as antidepressants 33
 side effects 33
 switching 35
 use with triptans 34
 self-functioning 121
 sensory auras 10
 serotonergic pathways 98
 serotonin 4, 12
 selective agonists (i.e., triptans) 4
 serotonin antagonist 13
 serotonin syndrome 18, 34
 Hunter Serotonin Toxicity Criteria 34

Index

- shunts, ventriculoperitoneal and ventriculoatrial 87
- sigma R receptor agonists 17
- sinus headache 13
- sleep 101
- social anxiety disorder 44
- somatic pain 132
- somatization 121
 as a process 149–151
- somatization disorders 77, 90, 149–161
 classification 151
 clinical features 156
 DSM-IV 151
 epidemiology 155
 and headache 156
 psychodynamic theories 149–150
 somatic amplification theory 150–151
 treatment 156
 and undifferentiated somatoform disorder 155
see also conversion disorder
- somatoform disorders and headache 149–161
 hypochondriasis 156–157
 screening 159
- somatosensory amplification 150
- SPECT 83
- stress
 behavioral management
 home-based behavioral therapy 59
 lay trainers 59–60
 chronic daily headache (CDH) 57
 risk factors 57
 defined 54, 106
 depression and /or panic attacks/ anxiety, co-occurrence 56
 electroencephalogram feedback (EEG-FB) 60
 electromyographic feedback (EMG-FB) 60
 episodic migraine (EM), chronic daily headache and PTSD 57
 estrogen hormones 55
 gender roles in stress reactivity 55
 headache 54–61
 hypothalamic–pituitary–adrenal axis (HPA) and cortisol axis 54, 55
 medication overuse 57, 102
 Midlife Development in United States (MIDUS) 56
 migraine, risk for first-onset major depression 56
 National Co-morbidity Survey Replication (NCR-R) results 57
 neuroticism 56
 perception 106
- personality traits and psychiatric disorders, comorbid conditions in migraine and mediators of stress 55
- posttraumatic stress disorder (PTSD) 44–45, 56, 57
- psychiatric modulators 56
- QEEG neurofeedback 61
- Self-Administered Behavioral Intervention using Tailored Messages (SEABIT) 59
- SMILE study 59
- tension-type headache (TTH) 24
 triggers 54, 55
- stress management techniques 58–61, 106–116, 108–114
 acupuncture 115
 autogenic training (AT) 108
 behavioral management
 multidisciplinary approach, results 61
 self-efficacy scale 58
 biofeedback 60, 110–112
 blood-volume–pulse feedback BP (BVP-FB) 60
 meta-analysis 60
 cognitive behavioral therapy (CBT) 58–60
 requiring trained personnel 59
 cognitive-behavioral therapy (CBT) 49, 112–114
 coping skills 114
 electromyographic biofeedback (EMG-FB) 109, 111
 galvanic skin response training (GSR-FB) 60
 guidelines 107
 hypnosis and imagery 109
 meditation 109
 pharmacologic options 58
 relaxation therapy (RT) 60, 108–109
 self efficacy scale 58
 support groups 114
 temperature feedback (TEMP-FB) 60
 thermal biofeedback 110
 treatment goals 107–108
 yoga 114
- stroke
 post-stroke depression 78
 post-stroke psychotic symptoms 78
- study design
 bidirectional causal model 3
 case controlled studies 2
 cross sectional studies 2
 prospective or cohort studies, defined 2
- subarachnoid hemorrhage 78
- substance abuse/dependence *see* drug dependence
- suicide attempts, associated with migraine and bipolar affective disorders 32
- syphilitic infection 87
- systemic disease
 involving brain 78
 personality change 121
- systemic lupus erythematosus 78
- Tai Chi 138–139
- Tanacetum parthenium* 18, 133
- technetium or radio-iodine imaging of thyroid 90
- telmisartan 17
- temporal arteritis 79
- temporomandibular disorders 24
- tension-type headache (TTH) 9, 13, 21–27, 97, 98
 chronic tension-type headache (CTTH) 21, 25, 98
 classification and description 21
 comorbidity 24
 diagnosis and investigation 22–23
 secondary headache 22, 24
 vs. migraine headache 23
 diagnostic criteria 22
- EMG activity, pericranial muscles 25
- epidemiology 23–24
- episodic tension-type headache (ETTH) 21, 23, 24
- management 27
 acute therapies 26
 behavioral therapies 25
 caffeine 26
 ibuprofen and naproxen 25
 mirtazapine 26
 non-pharmacological preventive therapies 26
 NSAIDs 25
 pharmacological preventive therapies 26, 27
 myofascial activity 25
 pathophysiology 24–25
 prognosis 27
 societal impact 23
 stress 24
 temporomandibular disorders 24
- testosterone, and antidepressants 36
- therapeutic alliance 125
- thermal biofeedback 49, 110
 training guidelines 110
- thyroid disease 80
- timolol 16
- tizanidine 17, 26
- Todd's paralysis 77
- tolerance, defined 63

- topiramate 16, 17, 38, 101
 trait domains 120
 tramadol dependence 67
 naloxone 67
 withdrawal 67
 transcranial magnetic stimulation (TMS) 141
 transference 125
 countertransference 125
 transformed migraine 97, 98
 transverse sinus thrombosis 78
 traumatic brain injury (TBI) 86
 trazadone 34
 tricyclic antidepressants (TCAs) 34
 interactions and side effects 38
 and stress management 38
 trigeminal autonomic cephalgia 97
 trigeminal ganglion, triptans 99
 triptans 13, 14, 15, 18, 26, 38
 injectable 15
 and NSAIDs 58
 trigeminal ganglion 99
 ubiquinone 134
 urea cycle enzymes 88
 US Headache Consortium
 grading system of non-pharmacological research 107
 guidelines 107
 valproic acid 17, 37
 interactions and side effects 38
 vasoactive intestinal peptide (VIP) 12
 venlafaxine 26
 ventriculoperitoneal and ventriculoatrial shunts 87
 verapamil 38
 visual hallucinations 85
 vitamin B2 134
 Wilson's disease 83–85
 ATP7B gene 83
 copper chelators 83
 Kayser–Fleischer rings 83
 wine 14
 yoga 114, 139
 yohimbine 67
 zonisamide 17